Join the 'Overactive Bladder' group to help and get support from people like you.

Overactive Bladder Blog

Related terms: Bladder Hyperactivity, Chronic overactivity of the bladder, Detrusor hyperreflexia, Detrusor instability, Incontinence, Urge, Irritable Bladder, Spasmodic Bladder, Unstable Bladder, Urge Incontinence, Urinary Frequency, OAB

Bathroom Visits May Add to Sleep Problems for Seniors

Posted 14 Mar 2013 by Drugs.com

THURSDAY, March 14 – Having to get up at night to urinate may worsen the already poor sleep of older people with insomnia, a new study suggests. Treatment of this problem, called nocturia, might help improve the sleep quality among these seniors, the researchers said. The study included older men and women with insomnia. Their patterns of sleeping and waking up to urinate during the night were evaluated for two weeks. The investigators found that 54 percent of all nighttime awakenings were associated with having to urinate. The more often a person had to go to the bathroom during the night, the poorer their self-reported quality of sleep, according to the study, which was published online March 15 in the Journal of Clinical Sleep Medicine. In addition, the study authors noted that nighttime awakenings were 11.5 percent longer on nights when people had to go to the bathroom. Waking up ... Read more

Related support groups: Sleep Disorders, Overactive Bladder

FDA Approves Over-the-Counter Oxytrol for Women to treat Overactive Bladder

Posted 25 Jan 2013 by Drugs.com

January, 25, 2013 – The U.S. Food and Drug Administration today approved Oxytrol for Women, the first over-the-counter treatment for overactive bladder in women ages 18 years and older. Oxytrol will remain available for men with overactive bladder by prescription only. Overactive bladder is a condition in which the bladder squeezes too often or squeezes without warning. Symptoms include leaking urine (urinary incontinence), feeling the sudden and urgent need to urinate, and frequent urination. Overactive bladder affects an estimated 33 million Americans, the majority of whom are older women. Oxytrol for Women contains oxybutynin, a medicine that helps relax the bladder muscle. Oxybutynin belongs to a class of drugs known as anticholinergics. It is the first drug in this class to be made available over-the-counter for treatment of overactive bladder. Oxytrol for Women is a patch ... Read more

Related support groups: Overactive Bladder, Oxybutynin, Oxytrol

First OTC Drug Approved for Women With Overactive Bladder

Posted 25 Jan 2013 by Drugs.com

FRIDAY, Jan. 25 – The drug Oxytrol has been approved by the U.S. Food and Drug Administration as the first over-the-counter treatment for women 18 and older with overactive bladder. Overactive bladder is characterized by symptoms including leakage, frequent urination and feeling the sudden and urgent need to urinate. The condition affects some 33 million Americans, mostly older women. Oxytrol contains oxybutynin, among a class of drugs called anticholinergics that are designed to relax the bladder muscle. Oxytrol is a patch applied to the skin every four days, the FDA said in a news release. The drug will remain available for adult men by prescription only, the agency said. Side effects reported during clinical testing included skin irritation at the patch site, dry mouth and constipation. Oxytrol for Women is marketed by Merck, based in Whitehouse Station, N.J. More information To ... Read more

Related support groups: Overactive Bladder, Oxybutynin, Ditropan, Oxytrol, Gelnique, Ditropan XL, Urotrol, Anturol

Botox Approved for Overactive Bladder

Posted 22 Jan 2013 by Drugs.com

TUESDAY, Jan. 22 – U.S. Food and Drug Administration approval of Botox (onabotulinumtoxinA) has been expanded to include adults with overactive bladder who don't respond to a class of drugs called anticholinergics. Overactive bladder's typical symptoms including leakage, frequent urination and feeling the sudden and urgent need to urinate. Botox, when injected into the bladder, causes it to relax and increases its capacity, the FDA said in a news release. In a clinical study, people treated with Botox after 12 weeks had urinary incontinence 1.6 to 1.9 times less per day than people treated with a placebo, the FDA said. The most common adverse reactions recorded during the study included urinary tract infection, painful urination and incomplete bladder emptying (urinary retention). People who develop urinary retention may have to use a catheter until the situation resolves, the agency ... Read more

Related support groups: Overactive Bladder, Botox, Botox Cosmetic, Onabotulinumtoxina

FDA Gives Nod to Botox to Treat Overactive Bladder

Posted 21 Jan 2013 by Drugs.com

FRIDAY, Jan. 18 – The U.S. Food and Drug Administration on Friday gave its approval for the use of Botox against a form of urinary incontinence known as overactive bladder. "Clinical studies have demonstrated Botox's ability to significantly reduce the frequency of urinary incontinence," Dr. Hylton Joffe, director of the Division of Reproductive and Urologic Products in the FDA's Center for Drug Evaluation and Research, said in an agency news release. "Today's approval provides an important additional treatment option for patients with overactive bladder, a condition that affects an estimated 33 million men and women in the United States," he added. Overactive bladder is a condition where the bladder contracts too frequently or without warning, causing incontinence, sudden/urgent urge to urinate and frequent urination. However, injections of Botox (onabotulinumtoxinA) into the bladder ... Read more

Related support groups: Overactive Bladder, Botox, Botox Cosmetic, Onabotulinumtoxina

FDA Approves Botox to Treat Overactive Bladder

Posted 18 Jan 2013 by Drugs.com

January 18, 2013 – The U.S. Food and Drug Administration today expanded the approved use of Botox (onabotulinumtoxinA) to treat adults with overactive bladder who cannot use or do not adequately respond to a class of medications known as anticholinergics. Overactive bladder is a condition in which the bladder squeezes too often or squeezes without warning. Symptoms include leaking urine (urinary incontinence), feeling the sudden and urgent need to urinate, and frequent urination. When Botox is injected into the bladder muscle, it causes the bladder to relax, increasing the bladder’s storage capacity and reducing episodes of urinary incontinence. Injecting the bladder with Botox is performed using cystoscopy, a procedure that allows a doctor to visualize the interior of the bladder while Botox is being injected. “Clinical studies have demonstrated Botox’s ability to significantly redu ... Read more

Related support groups: Overactive Bladder, Botox, Onabotulinumtoxina

Botox Injections: Option for Urge Incontinence?

Posted 4 Oct 2012 by Drugs.com

THURSDAY, Oct. 4 – Botulinum toxin, the anti-wrinkle treatment known as Botox, can also help women with urge incontinence reduce their leaking episodes, according to a new study. Injecting Botox into the bladder worked as well as daily solifenacin pills, a commonly prescribed treatment for incontinence, the researchers found. The Botox treatment is already approved by the U.S. Food and Drug Administration for urge incontinence due to known neurological injuries such as spinal cord trauma, said lead study Dr. Anthony Visco, chief of urogynecology and reconstructive pelvic surgery at Duke University Medical Center in Durham, N.C. It is not yet approved for incontinence without a recognized cause, known as idiopathic incontinence. Visco and his colleagues conducted what they believe is the first head-to-head comparison of medication and the botulinum toxin. They will present their results ... Read more

Related support groups: Overactive Bladder, Urinary Incontinence, Botox, Botox Cosmetic, Onabotulinumtoxina

FDA Approves Myrbetriq for Overactive Bladder

Posted 28 Jun 2012 by Drugs.com

June 28, 2012 - The U.S. Food and Drug Administration today approved Myrbetriq (mirabegron) to treat adults with overactive bladder, a condition in which the bladder muscle cannot be controlled, squeezes too often or squeezes without warning. An extended-release tablet taken once daily, Myrbetriq improves the storage capacity of the bladder by relaxing the bladder muscle during filling. Symptoms of overactive bladder include the need to urinate too often (urinary frequency), the need to urinate immediately (urinary urgency), and the involuntary leakage of urine as a result of the need to urinate immediately (urge urinary incontinence). “An estimated 33 million Americans suffer from overactive bladder, which is uncomfortable, disrupting and potentially serious,” said Victoria Kusiak, M.D., deputy director of the Office of Drug Evaluation III in the FDA’s Center for Drug Evaluation and R ... Read more

Related support groups: Overactive Bladder

Myrbetriq Approved for Overactive Bladder

Posted 28 Jun 2012 by Drugs.com

THURSDAY, June 28 – Myrbetriq (mirabegron) has been approved to treat adults with overactive bladder, a condition affecting some 33 million Americans, the U.S. Food and Drug Administration said Thursday in a news release. The drug is designed to relax the bladder muscle as the bladder fills, minimizing the potential symptoms of needing to urinate too often, needing to urinate immediately or the involuntary leakage of urine, the agency said. The drug's safety and effectiveness were evaluated in clinical studies involving 4,116 people with overactive bladder. The most common side effects were a rise in blood pressure, cold-like symptoms, urinary tract infection, constipation, fatigue, increased heart rate and abdominal pain. Myrbetriq is marketed by Astellas Pharma US, based in Northbrook, Ill. More information The U.S. National Library of Medicine has more about overactive bladder. Read more

Related support groups: Overactive Bladder

Urinary Incontinence Drugs May Be More Trouble Than They're Worth

Posted 9 Apr 2012 by Drugs.com

MONDAY, April 9 – For women with urinary incontinence, the available treatments may cause more problems than they solve and many stop taking the medications because of side effects that can include dry mouth and constipation, a new analysis indicates. Urge incontinence is marked by frequent, sudden urges to urinate that can result in leakage and accidents. Standard treatment includes lifestyle changes, pelvic floor exercises, bladder training and/or medication. There are several types of medications that may be used alone or together for the condition. Generally, these medications relax bladder contractions and help improve bladder function. Researchers from the University of Minnesota School of Public Health analyzed data from 94 studies to see how well the available drugs worked. A given medication was deemed effective if women achieved a 50 percent or more reduction in daily ... Read more

Related support groups: Overactive Bladder, Urinary Incontinence, Oxybutynin, VESIcare, Toviaz, Ditropan, Detrol, Oxytrol, Detrol LA, Gelnique, Solifenacin, Ditropan XL, Tolterodine, Urotrol, Fesoterodine, Anturol

Antares' Oxybutynin Gel Product Approved by FDA for the Treatment of Overactive Bladder

Posted 8 Dec 2011 by Drugs.com

PARSIPPANY, N.J. and EWING, N.J., Dec. 8, 2011 /PRNewswire/ – Watson Pharmaceuticals, Inc. and Antares Pharma, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Antares' topical oxybutynin gel 3% product for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency. OAB is a condition that affects more than 33 million Americans, and the market currently exceeds $2.0 billion annually. Antares' oxybutynin product is a clear, odorless topical gel available in a convenient, metered-dose pump that has demonstrated to be an effective and safe treatment for overactive bladder (OAB). Because the active ingredient is delivered transdermally, it is not metabolized by the liver in the same way as orally administered oxybutynin. This results in a low level of side effects, such as dry mouth and constipation. ... Read more

Related support groups: Overactive Bladder, Oxybutynin

Gelnique Approved for Overactive Bladder

Posted 28 Jan 2009 by Drugs.com

WEDNESDAY, Jan. 28 – The U.S. Food and Drug Administration has approved Watson Pharmaceuticals' Gelnique (oxybutynin chloride) to treat symptoms of overactive bladder, the company said in a news release. Gelnique is a topical gel that's applied daily to the thigh, abdomen, upper arm or shoulder. Since it's absorbed through the skin, it's not metabolized by the liver as it would be were the drug's active ingredient, oxybutynin, taken orally, Watson said. The most frequent side effects reported during clinical testing included dry mouth and reactions where the gel was applied. Overactive bladder, with symptoms including incontinence, urgency and waking up at night to urinate, affects as many as 33 million adults in the United States, the company said. More information The U.S. National Institute on Aging has more on urinary incontinence. Read more

Related support groups: Overactive Bladder

Ask a Question

Further Information

Related Condition Support Groups

Urinary Incontinence

Related Drug Support Groups

Flomax, Botox, tamsulosin, oxybutynin, VESIcare, Toviaz, Enablex, belladonna, Myrbetriq, view more... Ditropan, Detrol, Sanctura, Oxytrol, Detrol LA, saw palmetto, Gelnique, solifenacin, trospium, Sanctura XR, mirabegron, darifenacin, Ditropan XL, tolterodine, nettles, pennyroyal, B & O Supprettes, belladonna/opium, Urotrol, onabotulinumtoxina, Belladonna Tincture, fesoterodine, Prostate SR, Anturol, Urispas, flavoxate, Regurin